Targeting the Fas/Fas ligand pathway in cancer

Typeset version

 

TY  - JOUR
  - O'Brien, D. I. and Nally, K. and Kelly, R. G. and O'Connor, T. M. and Shanahan, F. and O'Connell, J.
  - 2005
  - Expert Opinion on Therapeutic Targets
  - Targeting the Fas/Fas ligand pathway in cancer
  - Validated
  - ()
  - 9
  - 5
  - 1031
  - 1044
  - Fas is a transmembrane receptor that can induce apoptosis after cross-linking with either agonistic antibodies or with Fas ligand (Fast). Although originally described as an important regulator of peripheral immune homeostasis, accumulating evidence suggests that the Fas/FasL system plays an important role in tumour development. In addition to its proapoptotic functions, accumulating evidence demonstrates that Fas can activate numerous nonapoptotic signalling pathways, and that activation of these pathways can result in increased tumourigenicity and metastasis. This review summarises the current understanding of the Fas/FasL system in tumorigenesis and discusses attempts to utilise the Fas/FasL system in the treatment of cancer.
DA  - 2005/NaN
ER  - 
@article{V122827788,
   = {O'Brien, D. I. and Nally, K. and Kelly, R. G. and O'Connor, T. M. and Shanahan, F. and O'Connell, J.},
   = {2005},
   = {Expert Opinion on Therapeutic Targets},
   = {Targeting the Fas/Fas ligand pathway in cancer},
   = {Validated},
   = {()},
   = {9},
   = {5},
  pages = {1031--1044},
   = {{Fas is a transmembrane receptor that can induce apoptosis after cross-linking with either agonistic antibodies or with Fas ligand (Fast). Although originally described as an important regulator of peripheral immune homeostasis, accumulating evidence suggests that the Fas/FasL system plays an important role in tumour development. In addition to its proapoptotic functions, accumulating evidence demonstrates that Fas can activate numerous nonapoptotic signalling pathways, and that activation of these pathways can result in increased tumourigenicity and metastasis. This review summarises the current understanding of the Fas/FasL system in tumorigenesis and discusses attempts to utilise the Fas/FasL system in the treatment of cancer.}},
  source = {IRIS}
}
AUTHORSO'Brien, D. I. and Nally, K. and Kelly, R. G. and O'Connor, T. M. and Shanahan, F. and O'Connell, J.
YEAR2005
MONTH
JOURNAL_CODEExpert Opinion on Therapeutic Targets
TITLETargeting the Fas/Fas ligand pathway in cancer
STATUSValidated
TIMES_CITED()
SEARCH_KEYWORD
VOLUME9
ISSUE5
START_PAGE1031
END_PAGE1044
ABSTRACTFas is a transmembrane receptor that can induce apoptosis after cross-linking with either agonistic antibodies or with Fas ligand (Fast). Although originally described as an important regulator of peripheral immune homeostasis, accumulating evidence suggests that the Fas/FasL system plays an important role in tumour development. In addition to its proapoptotic functions, accumulating evidence demonstrates that Fas can activate numerous nonapoptotic signalling pathways, and that activation of these pathways can result in increased tumourigenicity and metastasis. This review summarises the current understanding of the Fas/FasL system in tumorigenesis and discusses attempts to utilise the Fas/FasL system in the treatment of cancer.
PUBLISHER_LOCATION
ISBN_ISSN
EDITION
URL
DOI_LINK
FUNDING_BODY
GRANT_DETAILS